Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrina Meeth

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Immunohorizons|June 20, 2020
TLR Stimulation Produces IFN-β as the Primary Driver of IFN Signaling in Nonlymphoid Primary Human CellsRyan Nistler, Ankur Sharma, Katrina Meeth, et al.
Journal of the American Chemical Society|July 9, 2010
Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylationRong Huang, Marc A Holbert, Mary Katherine Tarrant, et al.
Cell Metabolism|March 26, 2019
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are LimitingMark R Sullivan, Katherine R Mattaini, Emily A Dennstedt, et al.
Cancer Immunology Research|September 4, 2016
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T CellsBlanca Homet Moreno, Jesse M Zaretsky, Angel Garcia-Diaz, et al.
Nature Medicine|February 13, 2018
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activationQian Xiao, Jibo Wu, Wei-Jia Wang, et al.
Cancer Cell|January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formationWilliam Damsky, Goran Micevic, Katrina Meeth, et al.
Cancer Research|February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic TargetsMarzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
Immunity|August 17, 2017
The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma ProgressionWen Pan, Shu Zhu, Kun Qu, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
Nature|July 8, 2016
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Immunohorizons|June 20, 2020
TLR Stimulation Produces IFN-β as the Primary Driver of IFN Signaling in Nonlymphoid Primary Human CellsRyan Nistler, Ankur Sharma, Katrina Meeth, et al.
Journal of the American Chemical Society|July 9, 2010
Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylationRong Huang, Marc A Holbert, Mary Katherine Tarrant, et al.
Cell Metabolism|March 26, 2019
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are LimitingMark R Sullivan, Katherine R Mattaini, Emily A Dennstedt, et al.
Cancer Immunology Research|September 4, 2016
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T CellsBlanca Homet Moreno, Jesse M Zaretsky, Angel Garcia-Diaz, et al.
Nature Medicine|February 13, 2018
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activationQian Xiao, Jibo Wu, Wei-Jia Wang, et al.
Cancer Cell|January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formationWilliam Damsky, Goran Micevic, Katrina Meeth, et al.
Cancer Research|February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic TargetsMarzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
Immunity|August 17, 2017
The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma ProgressionWen Pan, Shu Zhu, Kun Qu, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
Nature|July 8, 2016
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Pageof 3